<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2522">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128331</url>
  </required_header>
  <id_info>
    <org_study_id>PERMIT-HGW-DZHK40</org_study_id>
    <nct_id>NCT05128331</nct_id>
  </id_info>
  <brief_title>sPERMIdine supplemenTation on Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING</brief_title>
  <acronym>PERMIT_EX</acronym>
  <official_title>The Effect of sPERMIdine supplemenTation on the Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING in Patients With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores whether spermidine supplementation improves the metabolic,&#xD;
      neurological-cognitive and cardiovascular response to structured exercise training in&#xD;
      patients with heart failure with preserved ejection fraction. The investigators aim to show&#xD;
      that a faster adaptation to exercise may improve long term adherence to a more active&#xD;
      lifestyle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure with preserved ejection fraction is the largest unmet need in medicine.&#xD;
      Exercise training is a pivotal lifestyle intervention which has been shown to have beneficial&#xD;
      effects with regards to metabolic, neurological-cognitive and cardiovascular outcomes in&#xD;
      these patients. Yet, not every patients responds equally fast to an exercise training&#xD;
      intervention. This trial explores whether the supplementation of spermidine can increase the&#xD;
      response to a structured aerobic exercise training. The investigators will recruit 30&#xD;
      patients who will either receive a spermidine supplement or a placebo. The study participants&#xD;
      are invited for a first follow-up visit after four weeks. The exercise intervention starts at&#xD;
      week 5 and continues for 12 weeks. Hence, overall there are three visits (baseline, week four&#xD;
      and week twelve).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiorespiratory exercise capacity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in cardiorespiratory exercise capacity (VO2peak) in ml/min/kg before and after of exercise training</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in diastolic function based on echocardiography (E/e')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Reactive hyperemia index assessed using EndoPat</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Multiple-Choice Vocabulary Intelligence Test (MWT-B)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Multiple-Choice Vocabulary Intelligence Test: Measure: total number of correctly checked lines. Final outcome: IQ (standard value and percentile rank)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mnemonic Similarity Task (MST)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mnemonic Similarity Task (MST). % of correctly answered tasks (0 - 100 %). final outcome: D - Prime</description>
  </other_outcome>
  <other_outcome>
    <measure>Verbal Learning and Memory Test (VLMT)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Verbal Learning and Memory Test (VLMT) % of correctly answered tasks (0 - 100 %). final outcome: D - Prime</description>
  </other_outcome>
  <other_outcome>
    <measure>Digit Span test battery for attention testing</measure>
    <time_frame>16 weeks</time_frame>
    <description>Digit Span test battery for attention testing; from 0 to 8, Score: maximum number of digits that were correctly remembered after 3 erros the test ends. direction of the task (forward or backwards), the longest sequence successfully reached and passed, and the total number of attempts</description>
  </other_outcome>
  <other_outcome>
    <measure>brain magnetic resonance imaging (MRI) - T1</measure>
    <time_frame>16 weeks</time_frame>
    <description>brain magnetic resonance imaging (MRI) T1 to assess cortical brain structure pre and post intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>brain magnetic resonance imaging (MRI) - FLAIR</measure>
    <time_frame>16 weeks</time_frame>
    <description>brain magnetic resonance imaging (MRI) - FLAIR to assess white matter hyperintensities pre and post intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>brain magnetic resonance imaging (MRI) - DTI</measure>
    <time_frame>16 weeks</time_frame>
    <description>brain magnetic resonance imaging (MRI) - DTI to assess fractional anisotropy and fiber tracking pre and post intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>brain magnetic resonance imaging (MRI) - resting state fMRI</measure>
    <time_frame>16 weeks</time_frame>
    <description>brain magnetic resonance imaging (MRI) resting state fMRI to assess brain network connectivity pre and post intervention</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Spermidine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants are provided with spermidine supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants are provided with a placebo supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>spermidineLife</intervention_name>
    <description>dietary supplement that is made of natural wheat germ extract with high spermidine content, shiitake mushroom powder and immunoactive micronutrients⁴ (vitamin C and zinc) and vitamin B1.</description>
    <arm_group_label>Spermidine supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>dietary supplement that is made of cellulose.</description>
    <arm_group_label>Placebo supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diastolic heart failure (E/e' &gt; 8, left ventricular ejection fraction (LVEF) =&gt; 50 %,&#xD;
             dyspnea)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  nutritional supplements with polyamines&#xD;
&#xD;
          -  acute myo-, endo- or pericarditis&#xD;
&#xD;
          -  aortic valve stenosis (2nd degree)&#xD;
&#xD;
          -  cardiomyopathy or severe left ventricular hypertrophy (Interventricular septal end&#xD;
             diastolic thickness or posterior wall thickness &gt; 17 mm)&#xD;
&#xD;
          -  AV block (second degree)&#xD;
&#xD;
          -  pulmonary hypertension&#xD;
&#xD;
          -  thromboembolic event in the last six months&#xD;
&#xD;
          -  anemia&#xD;
&#xD;
          -  infection (with fever) within the last four weeks&#xD;
&#xD;
          -  cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcus Dörr, MD</last_name>
    <phone>+4938348680500</phone>
    <email>marcus.doerr@med.uni-greifswald.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Bahls, PhD</last_name>
    <phone>+4938348680500</phone>
    <email>martin.bahls@med.uni-greifswald.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular examination center of the University Medicine Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17489</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bahls, Ph.D.</last_name>
      <phone>+49 3834 8680500</phone>
      <email>martin.bahls@uni-greifswald.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Spermidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Our ethics approval does not allow to share IPD for this trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

